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Abstract
The possible different therapeutic efficacy of human mesenchymal stem cells (hMSC) derived from umbilical cord blood
(CB), adipose tissue (AT) or bone marrow (BM) for the treatment of myocardial infarction (MI) remains unexplored. This study
was to assess the regenerative potential of hMSC from different origins and to evaluate the role of CD105 in cardiac
regeneration. Male SCID mice underwent LAD-ligation and received the respective cell type (400.000/per animal)
intramyocardially. Six weeks post infarction, cardiac catheterization showed significant preservation of left ventricular
functions in BM and CD105
+-CB treated groups compared to CB and nontreated MI group (MI-C). Cell survival analyzed by
quantitative real time PCR for human GAPDH and capillary density measured by immunostaining showed consistent results.
Furthermore, cardiac remodeling can be significantly attenuated by BM-hMSC compared to MI-C. Under hypoxic conditions
in vitro, remarkably increased extracellular acidification and apoptosis has been detected from CB-hMSC compared to BM
and CD105 purified CB-derived hMSC. Our findings suggests that hMSC originating from different sources showed a
different healing performance in cardiac regeneration and CD105
+ hMSC exhibited a favorable survival pattern in infarcted
hearts, which translates into a more robust preservation of cardiac function.
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Introduction
Cell transplantation utilizing different cell types including
skeletal myoblasts [1,2], cardiomyocytes [3,4], smooth muscle
cells [5,6], bone marrow cells [7] and hematopoietic stem cells [8],
has emerged as a promising therapeutic avenue for cardiac
regeneration following myocardial infarction damage. Experimen-
tal and clinical evidences have demonstrated that transplanting
different cell types in the myocardium is safe and could contribute
to the angiogenesis in the infarcted area and the improvement of
cardiac functions [9–14].
Among the various cell types investigated, human mesenchymal
stem cells (hMSC) derived from adult tissues are an attractive stem
cell source in cardiac regeneration. hMSC are multipotent [15]
and capable of differentiating into cardiomyocytes [16] under
appropriate conditions. They express genes encoding for anti-
apoptotic, angio-/arteriogenic factors [17] and vascular endothe-
lial growth factor [18], and matrix-mediating factors [19].
Furthermore, hMSC can be easily isolated by plastic adherence
from bone marrow (BM), umbilical cord blood (UCB) or adipose
tissue (AT), and are culture expandable for therapeutic applica-
tion. hMSC derived from different sources have been well
characterized with respect to the isolation procedure, the cell
number, multilineage differentiation capacity [20–28], and aging
behavior of hMSC [29–32].
Wagner et al. evaluated hMSC from AT, UCB and BM in
terms of immune phenotype with a panel of 22 surface antigen
markers and analyzed their global gene expression profiles [33].
hMSC populations from different sources displayed similar
phenotypic characteristics and a consistent and reproducible gene
expression profile [33]. Kern et al. characterized the hMSC
pertaining to their morphology, frequency of colonies, expansion
characteristics, multilineage differentiation capacity, immunophe-
notype, and success rate of isolating the cells under identical in
vitro conditions [34]. Although phenotypically similar, these
culture-expanded hMSC exhibited cell source-related heteroge-
neity in colony frequency, proliferative potential and differentia-
tion potential [34], suggesting these different sources might greatly
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e15652affect the survivability and behavior of transplanted hMSC in the
hostile environment of ischemia, inflammation, pro-apoptotic
factors and scarring from myocardial infarction [35].
In this study we compared the therapeutic potential of hMSC
dervied from different sources in cardiac regeneration in a SCID
mouse left anterior descending (LAD) ligation model via
intracardiac injection with respect to cell survival, infarct size,
angiogenesis, cardiac remodelling and fuctional improvement. We
found that CD105
+ hMSC exhibited a favorable survival pattern
in infarcted hearts, which translated into a more robust
preservation of cardiac function.
Results
Immunophenotypic analysis and functional
differentiation
Cell isolation, expansion, characterization, and differentiation of
hMSC have been established according to previous reports [23,33].
The morphology of hMSC from different sources displayed a
homogenous spindle-shaped population and maintained a similar
morphology during the subsequent passages. FACS analysis was
employed to identify the surface marker expression at passage 3.
The hMSC culture was shown to be devoid of CD45, which is one
of the markers for hematopoietic cells. In contrast, a highexpression
of CD29, CD44, CD73 and CD105 markers were observed from
three different sources (Figure 1A). Compared to AT- and BM-
hMSC, CD105 expression level in CB-hMSC was significantly
lower(Figure 1AandTable1).TheresultsfromFACSanalysiswere
confirmed by immunocytochemistry (data not shown).
CD105
+ isolation
For characterization of isolated CD105
+ cells from human CB-
derived hMSC compared to unseparated CB group, surface
protein expression of 4 donors immediately after magnetic
separation were examined by flow cytometry. A high percentage
of cells express CD105 antigen with a mean value over 90% after
magnetic isolation whereas a smaller population below 80%
express CD105 antigen in unseparated CB group as previously
described by Kern et al [34] (Figure 1A). To observe the CD105
antigen presence in later passages of isolated CD105
+ cells, we
examined CD105 surface protein expression of 3 donors after
passage 4 and 5. During the growth of the cells in culture the
CD105 surface marker decreased over the culture time (Table 2).
hMSC can differentiate into multiple lineages (such as bone,
cartilage, and adipose tissue), and this ability is taken as a functional
criterion defining hMSC precursor cells [36]. To verify whether the
CD105 enrichment affected the differentiation capacity, the hMSC
from differentsourcesandCD105MSC-CBunderwentadipogenic,
and chondrogenic differentiation using the methods previously
described [37,38] at 24 hours post-enrichment. After 21 days of
induction toward an adipogenic lineage, a characteristic morpho-
logical change with accumulation of lipid vacuoles was observed
(Figure 1B left). Immunostaining revealed the presence of FABP-4,
which is a marker protein for adipocytes. Chondrogenesis was
assessed by immunostaining for aggrecan after 4 weeks of culture
under chondrogenic conditions. The chondrocyte-like cells showed
positive staining for aggrecan protein (Figure 1B right). Taken
together, this evidence indicated that hMSC prior to in vivo
experiment retain their multidifferentiation potential into adipo-
genic, and chondrogenic, lineages.
Cardiac functions
Hemodynamic measurement of the cardiac performance
(Figure 2A) demonstrates an improvement of functional param-
eters in case of stem cell treatment both under baseline conditions
as well as after stress induction. Figure 2A also shows improved
endsystolic values and stroke volume for hearts with implanted
human BM- and CD105-purified CB-hMSC (MI-CB105) com-
pared to MI-CB. Functional parameters in MI-BM and MI-
CD105 groups present significant improvements on ejection
fraction (EF) and stroke work (SW), both under baseline and
stress induction in comparison to the MI-CB (Figure 2B).
Significant values have also been found on stroke volume (SV),
endsystolic volume (ESV), maximum pressure (Pmax) and cardiac
output (CO; Figure 2B).
Infarct size
Ligation of the LAD consistently resulted in a transmural MI
with its typical histologic changes including the thinning of the left
ventricular free wall (Fast green) and extensive collagen deposition
(Sirius red) 6 weeks after infarction. Representative heart sections 6
weeks after myocardial infarction following hMSC application or
no injection of cells in the MI-C group are shown in Figure 3A. All
hMSC treated animals show a markedly smaller infarct size, while
the application of human BM- and CD105-purified CB-hMSC
could significantly reduce (p,0.05) the myocardial damage
compared to MI-C (Figure 3B).
Capillary density
The capillary density was determined by CD31-staining 6 weeks
after myocardial infarction. Examples of staining from the BZ
(border zone) of the infarct area present a lower capillary density in
MI-CB treated hearts and the MI-C group. (Figure 4A) Both, at
the BZ as well as the RA (remote area), hearts implanted with AT-,
BM- and CD105-purified CB-hMSC show a significant higher
capillary density compared to hearts which have been treated with
cells derived from CB (MI-CB) and the MI-C group, respectively
(Figure 4B).
Cardiac remodeling
Postinfarct cardiac remodeling serves as an important compen-
satory mechanism of congestive heart failure, characterized by
progressive ventricular chamber dilatation, hypertrophy, fibrosis
and prolonged cardiomyocyte apoptosis. Fibrosis resulted in
extensive collagen deposition (Sirius red) and increased distance
between myocytes (Fast green) 6 weeks after infarction. Figure 5A
shows representative staining images from the BZ indicating a
higher portion of collagen deposition in the MI-CB and the MI-C
group. Hearts implanted with CD105-purified CB-hMSC showed
a significant decrease of collagen deposition compared to MI-CB
and the MI-C group, respectively in RA and in the BZ (Figure 5B).
Figure 6A represents apoptotic nuclei of cardiomyocytes 6 weeks
after myocardial infarction. A significantly reduced percentage of
apoptotic cardiomyocytes could be found in the BZ of hearts
implanted with CD105-purified CB-hMSC and BM-hMSC,
respectively, compared to the MI-C group (Figure 6B).
Engraftment and characterization of hMSC in infarcted
murine hearts
We evaluated human GAPDH expression at 3 different parts
from the infarction area and identified implanted cells in the
mouse tissue 6 weeks after myocardial infarction following hMSC
application with selective binding human nuclei antibody (HNA)
(Figure 7A). Double immunofluorescence staining with HNA and
CD31 antibody revealed that at least some of the hMSC appeared
to display endothelial cell-like phenotype (Figure 7B). Six weeks
after cell transplantation, we observed a very low number of
CD105
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The frequency of cTnT-HNA double-positive cells from the
engrafted stem cells was extremely low. There was no significant
difference between different hMSC groups. It was not clear
whether the transplanted cells had fused or differentiated into
cardiomyocytes. Furthermore, higher human GAPDH expression
was detected in the lower and the middle section of the infarcted
hearts transplanted with BM-hMSC and CD105-purified CB
derived hMSC in comparison to MI-AT and MI-CB (Figure 7D).
There were no significant differences in the upper heart section.
Figure 1. Phenotypic characterization of hMSC from different sources. A. FACS analysis showed that the cells were negative for CD45
expression and positive for CD29, CD44, CD73 and CD105, which are phenotypes currently known to be characteristic of hMSC. The gray line
indicates the control of the CD marker isotypes. B. In vitro differentiation capacity of transplanted hMSC. hMSC from bone marrow were cultured in
adipogenic and chondrogenic medium. Chondrogenic differentiation (left). Immunostaining for aggrecan (red). Nuclei were counterstained with DAPI
(blue). Adipogenic differentiation (right). Immunostaining with fatty acid binding protein-4 (brown).
doi:10.1371/journal.pone.0015652.g001
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As the acidification is closely linked to the cellular energy
metabolism, we measured the acidification rate of hMSC under
normoxic as well as hypoxic conditions. While under normoxic
conditions the cells showed no significant difference (data not
shown), CB derived hMSC showed significantly higher metabolic
activity than AT-, BM- and CD105-purified CB-hMSC under
hypoxic conditions (Figure 8).
Tube formation of hMSC in vitro
To observe the influence of CD105 in the acceleration of
network formation we compared nature BM derived hMSC with
CD105 low BM-hMSC (antisense) using antisense phosphothiate-
ODN. Figure 9 shows the delivery efficiency of antisense into
hMSC and antisense delivery decreased network formation of
BM-hMSC compared to nature and scrambled group.
Cell proliferation of hMSC in vitro
T h eM T Ta s s a yi sw i d e l yu s e dt om e a s u r em e t a b o l i ca c t i v i t ya n d
cell proliferation. At different time points we detected metabolic activity
of BM105-antisense and BM105-scrambled. After 24 h we observed a
reduced viability for BM derived hMSC treated with BM105-antisense
compared to scrambled group. The antisense blocking of CD105
s e e m st ol o s ea tl a t e rt i m ep o i n t sw em e a s u r e d( F i g u r e9 C ) .
Discussion
The present study for the first time systematically evaluated the
cardiac regenerative capability of hMSC derived from different
human origins in a SCID mouse left anterior descending (LAD)
ligation model via intracardiac injection.
We showed that hMSC originating form different sources could
induce significant morphological and functional differences in
cardiac parameters. Infarcted hearts with hMSC-injection derived
from BM displayed (I) a significant improvement in myocardial
performance in comparison to those with hMSC-injection from
AT and CB. Furthermore, BM-hMSC treated animals presented
(II) a significantly reduced infarction area following diminished
cardiac remodeling and (III) a better capillary density in the
border zone of the MI. Significant higher localization of human
cells could be seen in the middle and apex section of BM-hMSC
treated hearts, which might be the result of a migration effect
similar than that seen by cardiac stem cells [39]. BM-derived
hMSC also showed (IV) the lowest metabolic activity in
comparison to all other cells. In addition, the definitive application
of a pure fraction of CD105
+-hMSC from CB revealed overall a
better myocardial performance than the whole proportion of CB
derived hMSC and was similar to that of the MI-BM group.
hMSC are found in many adult tissues and represent an
attractive stem cell pool due to their self renewing ability, high
proliferative capacity and mesodermal differentiation potential
[15]. For the isolation of hMSC, the BM displays one of the main
sources next to alternative sites such as CB and AT [26,28]. hMSC
derived from different human sources are well characterized and
share a consistent and reproducible gene expression profile [33],
however they may behave differently with respect to morphology,
expansion rate and differentiation potential under in vitro
conditions [34,40,41]. It has been not determined if there might
be therapeutic differences. In order to compare the differentiation
potential of hMSC originating from CB, AT and BM, a MI model
in the mouse was established as previously shown by our group
[42]. Herein we are able to analyze structural, functional and
molecular changes associated with acute MI.
Bieback and coworkers demonstrated that among different stem
cell surface markers (CD29, 44, 73, 90, 105), CD105 was
significantly lower expressed in CB-derived hMSC than in AT
and BM [34]. Therefore, we have also analyzed a very pure
fraction of CD105
+-hMSC derived from human CB, which has
been purified by an immunomagnetic isolation technique. CD105
or endoglin is a type I membrane glycoprotein, which is located on
the cell surface and is also part of the TGF-b receptor complex
[43]. Besides cytoskeletal organization, endoglin is also associated
with the development of the cardiovascular system and vascular
remodeling [43,44]. Furthermore, it is a proliferation-associated
and hypoxia-inducible protein which is efficiently expressed in
endothelial cells during (tumor) angiogenesis [43,45–47]. Hence,
low or less CD105 might be a potential candidate for the overall
worse performance of animals treated with the whole fraction of
CB-derived hMSC. Additionally, the results of presented study
show that after injection of the pure CD105
+-fraction nearly
equivalent values could be obtained as seen in the MI-BM-group.
This might be due to the fact that CD105
+-cells strongly activate
the TGF-b1 receptor pathway which can then interact with
downstream signaling to the Smad proteins, which seem to be
involved in cardiac fibrosis and scar remodeling [48,49]. The stem
cell surface marker CD105 additionally might be of importance
during the regeneration process of the infarcted heart. Herein it
could be shown that CD105 prevents hypoxia-induced apoptosis
in endothelial cells [50] and that downregulation of CD105
mRNA and protein expression resulted in a reduced inhibitory
effect of TGF-b1 on cell proliferation, migration and microvessel
formation [51]. Further studies with genetic manipulation of stem
cells by virus vector [52,53], nanoparticles [54,55] or gene-
activated matrix [56,57] and genome-wide transcriptome profiling
analysis [58] are necessary to elucidate the underlying mechanism
by which CD105
+-cells improve the therapeutic efficacy of cell
transplantation in treating myocardium.
Taken together, the presented study demonstrated that hMSC
display different regenerative effects in the post-infarct period.
Especially for CB-derived hMSC, this might be due the fact of low
Table 1. Immunophenotypic analysis of hMSC from different
origins.
Antibody CB AT BM
CD29 99,560,3 99,460,1 98,360,6
CD44 98,860,4 99,260,1 98,060,4
CD45 0,960,1 0,660,1 0,560,2
CD73 99,960,0 99,260,1 98,960,1
CD90 99,760,1 95,260,8 95,961,6
CD105 66,960,8* 90,065,2 97,361,0
n=3; mean [%]6SEM.
*p,0,05 compared to AT, BM.
doi:10.1371/journal.pone.0015652.t001
Table 2. CD105 expression in CB105
+ hMSC over the culture
time.
Antibody CB105
+ P3 CB105
+ P4 CB105
+ P5
CD105 99,060,2 80,361,0 59,661,0
n=3; mean [%]6SEM.
doi:10.1371/journal.pone.0015652.t002
CD105
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detailed evaluation of the different sources of hMSC prior to their
clinical application, in order to increase the patient benefit of stem
cell therapy after MI.
Materials and Methods
Culture of hMSC
For studies involving human tissues we obtained ethical
approval of the local ethical committees, Medical Ethics
Commission II, Medical Faculty Mannheim, Heidelberg Univer-
sity and Heidelberg University Ethical Board. The initial
approvals 48/05 (Medical Ethic Commission II) regarding
isolation of mesenchymal stem cells from umbilical cord blood
and 2006-192N-MA (Medical Ethic Commission II) regarding
isolation and characterisation of mesenchymal stem cells from
adipose tissue have been reconfirmed on 26.02.2009. Bone
marrow for research purposes was received according to the
approval by the Heidelberg University Ethical Board; approval
nos.: 251/2002 and S-076/2007. All samples were taken after
written consent using guidelines approved by the Ethic Committee
on the Use of Human Subjects at the University of Heidelberg.
According to requirements of the START-MSC-Project we
used hMSC from the three different human sources cord blood
(CB), bone marrow (BM), and adipose tissue (AT) which were
isolated and prepared as previously described in detail [34]. We
cultured all the hMSCs at 37uC at a humified atmosphere
containing 5% CO2 and a mean cell density of 461610
3/cm
2 in
stem cell medium (MSCGM; Lonza, Walkersville, MD, USA) to
70–80% confluency. Cells were harvested at sub-confluency using
trypsin. After the third passage, cells have been used for
subsequent in vitro and in vivo experiments.
CD105
+ separation
To isolate CD105
+ cells from human CB derived hMSC we
used magnetic separation with CD105 MicroBeads following the
instructions of MACSH (Miltenyi Biotec, Germany) using 20 ml
MicroBeads per 250.000 augmented hMSC. The positive fraction
was used for subsequent experimentation. A number of 10
7 cells
were resuspended in PBS with 2 mM EDTA and 0.5% bovine
serum albumin and loaded into the separation columns after
MicroBeads incubation. The positive fraction was used for in vivo
experiments without further culture. In order to analyze the
surface expression of CD105 by Flow Cytometry, magnetic
separation was carried on at passage 3. Subsequently, CD105
+
signal was monitored at passages 3, 4 and 5.
Immuno phenotypic analysis
Cell surface antigen phenotyping of CB, AT and BM derived
hMSC was performed at passage 3. CD105 expression level in
Figure 2. Heart functions 6 weeks after MI. A. Recovery of cardiac performance shows improvement for hearts with implanted human BM- and
CD105-purified CB-hMSC compared to MI-CB hearts. B. Left ventricular functions at both baseline and stress condition assessed by catheterization.
doi:10.1371/journal.pone.0015652.g002
CD105
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+ enriched CB-hMSC population was monitored at
passages 3, 4 and 5. The following cell-surface epitopes were
marked with the anti-human antibodies CD29-APC, CD44-
PerCP-Cy5,5, CD45-V500, CD73-PE, CD90-PE (Becton
Dickinson, Germany) and CD105-Alexa488 (AbD Serotec,
UK). Mouse isotype antibodies served as control. 2610
4 labeled
cells were acquired and analyzed using a FACS Scan flow
cytometer (LSRII) running with CellQuest-Software (Becton
Dickinson).
Experimental design of the animal model
The federal animal care committee of LALLF Mecklenburg-
Vorpommern (Germany) approved the study protocol (approval
number LALLF M-V/TSD/7221.3-1.1-036/07). SCID mice (strain
CB17/Icr-Prkdc-scid) were purchased from Charles River Labora-
tories (Sulzfeld, Germany). SCID mice (male, 2061 g, Charles River
Laboratories) were randomly assigned to 5 groups: Sham operation
(Sham, n=10) and 4 MI groups with implanted hMSC of the
respective source (MI-CB n=10, MI-CB105 n=10, MI-AT n=10,
Figure 3. Infarction size 6 weeks after MI. A. Representative ventricular cross sections of heart level c. B. Ratio of infarction size to entire LV is
significantly decreased in MI-BM and MI-CB105
+ compared to MIC.
doi:10.1371/journal.pone.0015652.g003
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TM
Matrix alone served as controls (MI-C n=10). A subset of randomly
selected mice (n=7) were assessed for functional measurement,
histological and real time polymerase chain reaction (real time-PCR)
evaluation at 6 weeks after LAD-ligation.
Generation of MI in mice and stem cell implantation
Mice were anesthetized with tribrom ethanol (AvertinH
0,35 mg/kg, intraperitoneal). After thoracotomy and preparation,
the left anterior descending coronary artery (LAD) was perma-
nently ligated. Immediately after LAD-ligation, each mouse
received an intramyocardial injection of 400.000 hMSC in BD
Matrigel
TM Matrix (BD Biosciences USA), or BD Matrigel
TM
Matrix alone for MI-C similar to a previous study [59]. Along the
border of the blanched myocardium 465 ml injections were given.
Sham operated mice underwent identical surgical procedures
without LAD-ligation but followed by intramyocardial BD
Matrigel
TM Matrix injection without cells.
Figure 4. Capillary density 6 weeks after MI. A. Representative endothelial CD31 staining at the infarction border zone of level c sections. B.
Capillary density in both the RA and the BZ of the LV is significantly higher in MI-AT, MI-BM and MI-CB105
+ compared to MIC.
doi:10.1371/journal.pone.0015652.g004
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Six weeks after surgery, mice underwent pressure-volume (P/V)
loop measurements according to the protocol of CardioDynamics
BV (CD Leycom, Zoetermeer, Netherlands). Data were collected
with the Millar Pressure-Volume System (Ultra-Miniature Pres-
sure-Volume Catheter (model SPR-1030), Millar Pressure Con-
ductance Unit (model MPCU-200) and Millar PowerLab data-
acquisition hardware; emka Technologies, Paris, France). Cali-
bration of pressure and volume was performed by equating the
minimal and maximal conductances with minimal (0 mmHg) and
maximal (100 mmHg) pressures as well as minimal and maximal
blood volumes received from venous circulation. After inserting
the catheter into the carotid artery, retrograde access to the left
ventricle (LV) was achieved. P/V loops were recorded under
normal conditions (baseline) followed by stress conditions medi-
ated by intravenous dobutamine administration (10 mg/kg/min,
Sigma-Aldrich, Deisenhofen, Germany). Volume signal was
corrected by measurement of wall conductance (parallel volume)
Figure 5. Fibrosis 6 weeks after MI. A. Representative Fast Green FCF (myocytes)/Sirius Red (fibrosis) stainings at the BZ. B. Significantly decrease
of collagen deposition has been shown in both the RA and the BZ in MI-CB105
+ compared to MI-CB and MI-C.
doi:10.1371/journal.pone.0015652.g005
CD105
+ hMSC in Cardiac Regeneration
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e15652via hypertonic saline (5%) injection. Data were analyzed with IOX
Version 1.8.3.20 software (emka Technologies). After P/V loop
measurements, mice were euthanized. Hearts were arrested in
diastole with potassium chloride. Each heart was removed,
embedded in O.C.T.
TM Compound (Tissue-TekH; Zoeterwoude,
Niederlande) and snap-frozen in liquid nitrogen. For histological
and biomolecular investigations the infarct area of heart tissue has
been divided into 4 horizontal levels from top to bottom within
each given amount of 5 mm sections were cut. The three
interlayers between the mentioned levels have been collected
separately for RNA isolation.
Infarction size and fibrosis analysis
Heart sections of 4 horizontal infarct levels (5 mm) were stained
with Fast Green FCF (Sigma-Aldrich) and Sirius Red (Division
Chroma, Mu ¨nster, Germany). Two contiguous levels of the heart
(n=7 for each group) which represent the major infarct ratio were
analyzed using computerized planimetry (Axio Vision LE Rel. 4.5
software; Zeiss, Jena, Germany). To evaluate fibrosis (n=5 for
each group), the sirius red positive regions of collagen deposition
in the remote area (RA) near endocardial border were examined
in 10 randomly chosen fields per section (one section per level;
6306) using computerized planimetry. Collagen density was
expressed as the ratio of collagen deposition to myocardial tissue
in percentage.
Late cardiomyocytes apoptosis
To analyse cardiomyocyte apoptosis, heart sections of two
contiguous levels of the heart (n=5 for each group) which
represent the major infarct ratio underwent terminal deoxynu-
cleotidyl transferase-mediated dUTP nick end-labelling assay
(DeadEnd Colorimetric TUNEL System; Promega; Madison,
WI, USA) according to the manufacturer’s instructions. Subse-
quently, slides were stained with rabbit polyclonal anti-troponin I
primary antibody (Santa Cruz; Santa Cruz, USA) and goat anti-
rabbit Alexa-FluorH 568 (Molecular Probes
TM; Carlsbad, USA)
conjugated secondary antibody, counterstained with TO-PROH-3
iodide (Molecular Probes
TM) for nuclei and examined with
confocal microscope. The number of TUNEL positive cardiomy-
ocytes was counted in 10 randomly chosen HPFs (6306) per
section (one section per level) for both RA and border zone (BZ;
n=5 for each group). Results were expressed as the proportion of
the TUNEL positive cardiomyocytes nuclei to the total number of
cardiomyocytes in percentage.
Determination of capillary density
For immunohistological detection of capillaries, heart sections of
two contiguous levels of the heart (n=5 for each group) which
represent the major infarct ratio were immunostained with
polyclonal goat anti-CD31 (Santa Cruz) primary antibody
followed by anti goat Alexa-FluorH 568 (Molecular Probes
TM)
conjugated secondary antibody and counterstained with DAPI.
Figure 6. Late cardiomyocytes apoptosis. A. Representative immunostaining for TUNEL (green) and cardiac troponin (red) at the BZ 6 weeks
after MI. B. Cardiomyocytes apoptosis was significantly reduced in the BZ in MI-BM and MI-CB105
+ compared to MI-C.
doi:10.1371/journal.pone.0015652.g006
CD105
+ hMSC in Cardiac Regeneration
PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e15652The sections were analyzed within the BZ and RA of the heart.
Capillary density was assessed by counting the number of
capillaries in 5 RA and 5 BZ randomly-chosen fields (4006).
Results were expressed as capillaries per high power field (HPF).
Human cell detection
For identification of implanted hMSC total RNA was isolated
from the three separately collected interlayers of cryosectioned
hearts (n=7 for each group) following the instructions of the
TRIZOLH Reagent (Invitrogen; Carlsbad, USA). For reverse
transcription of total RNA amount (2 mg) and first-strand synthesis
of cDNA, SuperScriptH III Reverse Transcriptase (Invitrogen) and
oligo (dT)15 Primer (Promega) were applied. Quantitative real
time-PCR was performed with StepOnePlus
TM Real-Time PCR
System (Applied Biosystems Foster City, CA, USA) in TaqManH
Universal Master Mix, No AmpEraseH UNG (Applied Biosystems)
according to the instructions of the manufacturer using the
following program: 1 cycle of 50uC for 2 min, 1 cycle of 95uC for
10 min, and 40 cycles of 95uC for 15 s and 60uC for 1 min.
Human GAPDH (TaqManH Gene Expression Assay ID:
Hs99999905_m1; Applied Biosystems) were tested in at least
triplicate, normalized against mouse GAPDH (Endogenous
Control: 4352339E) and negative controls were included in each
assay. Cycle thresholds (CT) for single reactions were determined
with StepOne
TM Software 2.0 (formula: DCT =C T hGAPDH -
CT mGAPDH; Applied Biosystems). Resulting DCT of triplicates was
averaged and reciprocated to present the quantity of attend
human cells. For immunohistological identification of human cells,
heart sections were immunostained following the instructions of
VectorH M.O.M.
TM Immunodetection Kit (LINARIS; Wertheim-
Bettingen, Germany) to localize mouse primary monoclonal and
polyclonal antibodies on mouse tissue using monoclonal anti-
human-nuclei (CHEMICON; Billerica, MA, USA) primary
antibody followed by anti mouse Alexa-FluorH 488 (Molecular
Probes
TM) conjugated secondary antibody and counterstained
with TO-PROH-3 iodide (Molecular Probes
TM).
Human cell differentiation potential
In order to investigate the differentiation capacity of hMSC
after transplantation into the infarcted heart multiple antibodies
Figure 7. Identification of transplanted hMSC in infracted myocardium. 6 weeks after MI: A–C. Representative immunofluorescent
micrographs of hearts transplanted with hMSC. A transplanted hMSC could be identified in infarcted myocardium B. A number of hMSC (Arrows,
human nuclei in green) were co-localized with CD31 positive cells (red). C. Occasionally hMSC (Arrow, human nuclei in green) co-localized with
cardiac troponin positive cell (red). (Confocal image, original magnification 6306) D. Quantitative real-time PCR analysis for human GAPDH
expression level at different infarction sections: MI-BM and MI-CB105
+ hearts show significantly higher localisation of human cells in the middle and
apex section.
doi:10.1371/journal.pone.0015652.g007
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primary antibody was initially applied to the section followed by
anti goat Alexa-FluorH 488 (Molecular Probes
TM) secondary
antibody incubation. Subsequently, human nuclei were stained
following the protocol previously described and a rabbit polyclonal
anti-troponin I primary antibody (Santa Cruz) was applied to the
sections. A goat anti-rabbit Alexa-FluorH 568 (Molecular Pro-
bes
TM) was utilized during secondary antibody reaction. Coun-
terstaining was achieved by TO-PROH-3 iodide (Molecular
Probes
TM) nuclear staining. The samples were analyzed using a
LSM 780 confocal microscopy (Carl Zeiss, Jena).
Real time acidification of viable hMSC in vitro
The silicon sensor chip technology allows the observation of
cellular behaviour in cell cultures. Online monitoring was
performed with the BionasH 2500 analyzing system (Bionas,
Rostock, Germany) [60,61]. The cells were seeded in duplicate
24 h before measurement directly on the chip surface to assure
highly specific signal detection. The cell concentration was
adapted in such a way that the cells reach approximately 80%
confluence on the sensor chip after 24 h. The measurement is
noninvasive and label-free. The media flow over the cells is
stopped periodically. Breakdown products (lactate, CO2) and the
oxygen consumption of cells result in a change of pH and oxygen
content in the medium. These changes are measured in the stop
phases of the pump cycle. In the following pump phase ‘‘used’’
medium is exchanged for fresh medium. The stop and go cycle of
8 min each is carried out over the whole experiment. Acidification
rates are calculated as the slope of changes in every stop phase
related to the basal signal in %. The changes of pH are measured
on the sensor chip by Ion Sensitive Field Effect Transistors
(ISFETs). For measurement in the BionasH 2500 analyzing system
medium without bicarbonate buffer (running medium) with 1 mM
HEPES, 0.1% FCS, 10.000 U penicillin and 10 mg streptomycin/
ml was used. The pH of the running medium was adjusted to 7.4
and the osmolarity to 290 mOsm/kg. For measurement under
hypoxic conditions the analyzing system was operating in a
nitrogen environment. At the end of the experiment the cells were
killed by addition of 0.2% Triton X-100 to the running medium to
get a basic signal without living cells on the sensor surfaces
(negative control).
In Vitro Functional Differentiation Assay
To induce adipogenic differentiation, hMSC from different
sources were seeded at a density of 3610
3 cells per cm
2 and
cultured for up to 3 weeks in cell culture medium supplemented
with 1028 M dexamethasone, 2.5 mg/ml insulin, and 100 mM
indomethacin. To induce chondrogenic differentiation, 3610
5
hMSC were cultured in 1 ml of chondrogenic induction medium
(cell culture medium supplemented with 0.1 mM dexamethasone,
1 mM sodium pyruvate, 0.17 mM l-ascorbic acid 2-phosphate,
0.35 mM l-proline, 6.25 mg/ml insulin, 6.25 mg/ml transferrin,
6.25 ng/ml selenite, 5.33 mg/ml linolic acid, 1.25 mg/ml bovine
serum albumin, and 0.01 mg/ml transforming growth factor-b3) in
the tip of a 15-ml conical tube to allow aggregation of the cells in
suspension culture. The induction of chondrogenic differentiation
was performed for 4 weeks. The differentiation capacity toward
different cell lineages was verified by morphology changes and
immunostaining for specific markers, that is, aggrecan for
chondrocytes and, fatty acid binding protein (FABP-4) for
adipocytes
Antisense-Oligodesoxynukleotide (ODN) blockade
BM-hMSC at passage 3 was seeded24 h beforetransfection.The
cell concentration was adapted in such a way that the cells reach
approximately 60% confluence on the well after 24 h. To reduce
the expression of CD105 in BM derived hMSC phosphothiate-
ODN with the antisense-sequence 59-ATGCTGTCCACGTGGG-
39 (Eurogentec, Germany) was transfected into the cells by
Lipofectamine 2000 (Invitrogen) as the manufacturer described. A
scrambled-ODN with the nonsense sequence 59-ACTCGTGC-
TACGGTGG-39 (Eurogentec) was used as control.
Tube forming assay
To observe the network formation potential of BM derived
hMSC with reduced expression compared to nature cells, BM-
Figure 8. Real time acidification rate as a live cell parameter. CB derived hMSC show significant increased metabolic activity under hypoxic
situation compared to BM- and CD105-purified CB-derived hMSC.
doi:10.1371/journal.pone.0015652.g008
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After 24 h 7610
4 cells were cultured in 4-well plates with 200 ml
BD Matrigel
TM Matrix (BD Biosciences) at 37uC and a humified
atmosphere containing 5% CO2. After 30 min 200 ml endothelial
cell medium (EGM-2; Lonza) was applied to each well, cultured
continuously and daily changed.
MTT assay
Before detection of metabolic activity of BM105-antisense and
BM105-scrambled with MTT (3-[4,5-Dimethyl-2-thiazolyl]-2,5-
diphenyl-2H-tetrazolium bromide; Sigma-Aldrich, St. Louis, MO,
USA) assay, BM-hMSC were precultured in 96-well plates and
transfected as described. After 24, 48 and 96 h of incubation at
37uC MTT (5 mg/ml in PBS) was added into each well. After 4 h
of incubation at 37uC, the medium was removed and the purple
crystals were dissolved in 100 ml dimethylsulfoxide (DMSO).
Absorbance was measured by a microplate reader (Model 680,
Bio-Rad) at a wavelength of 550 nm with a reference wavelength
of 655 nm. The results were expressed as the percentage of viable
BM105-antisense and BM105-scrambled with respect to BM105-
GFP. Cell viability was calculated using the following equation:
Cell Viability (%) = (OD550-OD655, samples)/(OD550-
OD655, control) 6100%
Statistical analysis
Statistical analysis was performed using SigmaStat 3.0 (Chicago,
USA). Results are expressed as mean 6 SEM. Overall
comparisons of the treatment groups were performed by using
the one-way analysis of variance (ANOVA) method that applies
post-hoc multiple Holm-Sidak tests, and by using the nonpara-
Figure 9. CD105 cell isolated from BM hMSC were transiently transfected with GFP, antisense-Oligodesoxynukleotide (ODN-
CD105), scramble ODN. A. Transfection efficiency is shown on the upper picture (GFP) B. Silencing of CD105 blocks BM-hMSC tube formation
compared to nature and scrambled group. The BM-hMSC were embedded in Matrigel and incubated in EGM-2 seven days after transfection and then
imaged. C. Cell proliferation was analyzed at 24, 48 and 96 h after the ODN-CD105 and scramble ODN transfection by MTT assay.
doi:10.1371/journal.pone.0015652.g009
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Dunn tests. P values ,0.05 were considered as statistically
significant.
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